No Weight Loss Benefit Seen for Neoadjuvant Semaglutide Before Weight Loss Surgery
No benefits seen in terms of weight loss, diabetes remission, surgery safety
Americans Borrowed $74 Billion in 2024 to Cover Medical Costs
Survey reveals many Americans worry they will incur medical debt if they experience a major medical event
Americans Borrowed $74 Million in 2024 to Cover Medical Costs
Survey reveals many Americans worry they will incur medical debt if they experience a major medical event
Risk for Specific Hematologic Cancers Down With GLP-1 Receptor Agonist Use in T2DM
GLP-1 RA use linked to lower risks for myelodysplastic syndromes, myeloproliferative neoplasms compared with metformin
Recent Decade Saw No Change in Diabetes Prevalence in U.S. Adults
However, glycemic control worsened, with the trend most pronounced among younger adults aged 20 to 44 years
Continuous Glucose Monitors Overestimate Glycemic Responses
Variation in CGM bias by postprandial test, with glycemic index for commercial fruit smoothie higher with CGM versus capillary sampling
Global Increases in Obesity Set to Continue in Children, Teens to 2050
And, the total number of adults living with overweight and obesity projected to reach 3.80 billion by 2050
One-Hour Glucose on OGTT at Three Months Postpartum Predicts Dysglycemia
One-hour glucose was strongest predictor of dysglycemia on regression analyses, followed by two-hour glucose
Sotagliflozin Cuts MACE Rate in Patients With T2DM, CKD, CVD Risk Factors
Sotagliflozin can also significantly reduce the rate of myocardial infarction and stroke compared with placebo
GLP-1 Receptor Agonist Use Not Linked to Increased Suicide Risk
After adjustment for confounding variables, no increased risk seen for GLP-1 receptor agonists versus DPP-4 inhibitors, SGLT-2 inhibitors
